- Conditions
- Esophageal Adenocarcinoma, Esophageal Cancer
- Interventions
- Standard of care chemotherapy, LNSC
- Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Weston, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 9,813
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- GSK3174998, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Selinexor, Docetaxel
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Pittsburgh, Pennsylvania • Nashville, Tennessee + 2 more
- Conditions
- Neoplasms, Breast
- Interventions
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 19
- States / cities
- Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more
- Conditions
- Ovarian Cancer
- Interventions
- Palliative Performance Scale version 2 (PPSv2), McCorkle Symptom Distress Scale (SDS), Geriatric Assessment, Medical Records Abstraction
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- Interventions
- Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Fort Wayne, Indiana • Lexington, Kentucky + 3 more
- Conditions
- Neoplasms
- Interventions
- Refametinib (BAY86-9766), Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Detroit, Michigan • St Louis, Missouri + 2 more
- Conditions
- Locally Advanced Head and Neck Carcinoma
- Interventions
- Soylent Graham Dietary Supplement, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Dietary Supplement · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Interventions
- PV701
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- MDV3100
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 3
- States / cities
- New York, New York • Norfolk, Virginia
- Conditions
- Solid Tumors
- Interventions
- Cobimetinib, Pictilisib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- Advanced Breast Cancer
- Interventions
- Initiation of ribociclib, Initiation of letrozole
- Drug
- Lead sponsor
- Shirley Vichy Wang
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- busulfan, melphalan, topotecan hydrochloride, laboratory biomarker analysis, filgrastim, autologous hematopoietic stem cell transplantation, pharmacological study, autologous bone marrow transplantation
- Drug · Other · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 6 Months to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Ribociclib, Fulvestrant, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Anaheim, California • Palo Alto, California • Jacksonville, Florida + 8 more
- Conditions
- Advanced Solid Tumor, Pain
- Interventions
- Meaning-Centered Pain Coping Skills Training
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Renal Cell Carcinoma
- Interventions
- CP-461
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, bevacizumab, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Brain Neoplasm
- Interventions
- Cyclophosphamide, Dasatinib, Laboratory Biomarker Analysis, Temsirolimus
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Months to 20 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Terminal Care, Neoplasm
- Interventions
- End of life care coordination, FairCare System
- Behavioral · Procedure
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Metastatic Breast Cancer
- Interventions
- biomarker study
- Other
- Lead sponsor
- Side-Out Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Miami, Florida + 4 more
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- INCAGN01876, retifanlimab
- Biological
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more
- Conditions
- Neoplasm Metastases
- Interventions
- RAD001 + AMG479
- Drug
- Lead sponsor
- Shadia Jalal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Melanoma
- Interventions
- Spartalizumab, Placebo, Dabrafenib, Trametinib
- Biological · Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 12
- States / cities
- Encinitas, California • Orange, California • San Francisco, California + 9 more
- Conditions
- Advanced Cancer
- Interventions
- care management by oncology nurses
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania